Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir
Bictegravir matches dolutegravir in first-line treatment
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects
Studies confirm long-term effectiveness of new single-tablet regimens
Doravirine combination works well as a switch option
Two new doravirine pills approved in US
Indonesia: tackling HIV in one of the world’s fastest-growing epidemics
Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients
Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment
